By using this site, you agree to the IDC Privacy Policy

Mar 2018 - IDC Perspective - Doc # US43590617

Roche Buys Flatiron Health: RWE Takes a Giant Step Forward

By: Alan S. Louie, Ph.D.Research Director, Life Sciences

Abstract

This IDC Perspective provides analyst insights on Roche's $1.9 billion acquisition of Flatiron Health. It also highlights Flatiron's efforts to develop a high-quality patient RWE resource and platform to help researchers, investigators, and clinicians to better leverage data to accelerate new drug research, streamline clinical trials, and improve patient outcomes.

"The effective use of new data available to life science companies promises to accelerate time to insights and time to market, which concurrently are improving operational excellence and reducing costs. High-quality RWE data will play a significant role in delivering on this promise with the Flatiron Health approach paving the way toward more mainstream use of this data," said Alan S. Louie, research director, IDC Health Insights Life Science R&D Strategies and Technology.


Coverage

Content


Related Links